Kai Di Sen international medical official website

 

CALGARY, AB / ACCESSWIRE / February 22, 2017 / Imaging Dynamics Company Ltd. ("IDC" or the "Company") (TSX-V: IDL) is pleased to announce that it received notification today that the United States Food and Drug Administration ("FDA") has granted Market Clearance (510k) approval for its new Digital Radiography ("DR") product line - Aquarius 8600 1717TC and Aquarius 8600 1417TC. These products utilize and integrate into IDC's proprietary Magellan Software and Work Stations. This approval now allows these products to be marketed for Human Use in the United States.

"IDC is excited to provide new and innovative technology to the US market. This is the foundation for a new beginning for IDC and is the result of a dynamic team effort," said Ms. Nicole Wherry, IDC's Chief Regulatory Officer.

This is a significant milestone for IDC as it allows the Company to offer its own proprietary flat panel DR products as an upgrade option to existing install bases.

About Imaging Dynamics Company (IDC):

IDC is a global medical imaging technology provider and innovative force in the high growth field of digital radiography (DR) technology.

The Company has thousands of installations in 50 countries of its proprietary, award winning direct capture DR technology, which replaces conventional film-based diagnostic imaging and provides a cost-effective solution for medical facilities of all sizes to provide high quality diagnostic X-ray images and improve the level of healthcare for their patients.

Throughout its history, IDC has been recognized by multiple industry organizations and research analysts such as: Frost & Sullivan and Deloitte Technology; for its dedication to innovation, global market growth, and customer focused value proposition.

The Company has its corporate office in Calgary, Canada, a sales and marketing office in Beijing, China, and also operations, research and development centres in Calgary, Canada and Shanghai, China. Visit the IDC web site: www.imagingdynamics.com

For more information, please contact:

Mr. Eugene Woychyshyn
Chief Financial Officer
1.403.251.9939 Office
1.866.975.6737 Toll Free
ewoychyshyn@imagingdynamics.com

Statements in this release which describe IDC's intentions, expectations or predictions, or which relate to matters that are not historical facts are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties which may cause the actual results, performances or achievements of IDC to be materially different from any future results, performances or achievements expressed in or implied by such forward-looking statements. IDC may update or revise any forward-looking statements, whether as a result of new information, future events or changing market and business conditions. Known and unknown risks and uncertainties include: IDC's ability to manufacture its products with a sufficient level of quality and in volumes which satisfy market demand; the ability of IDC to establish direct and indirect sales channels; the ability of IDC to establish industry partnerships; IDC's ability to attract and retain key personnel; the strength and breadth of IDC's patents; and other factors relating to general economic conditions, specific industry conditions and IDC's particular situation.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Imaging Dynamics Company Ltd.